Winter is coming—eventually. And while the Earth is warming, a new study suggests that the atmosphere is being pushed around in ways that cause long bouts of extreme winter cold or wet in some regions.

The study’s authors say they have identified giant meanders in the global jet stream that bring polar air southward, locking in frigid or wet conditions concurrently over much of North America and Europe, often for weeks at a time. Such weather waves, they say, have doubled in frequency since the 1960s. In just the last few years, they have killed hundreds of people and paralyzed energy and transport systems.

The new paper, titled “Recent Increase in a Recurrent Pan-Atlantic Wave Pattern Driving Concurrent Wintertime Extremes,” appears this week in the Bulletin of the American Meteorological Society.

Speaker: Robert Hyzy, MD

This lecture explores the use of non-invasive ventilation and high flow nasal cannula in patients with respiratory failure both as a means of avoiding endotracheal intubation and invasive mechanical ventilation as well as in preventing reintubation.

Cancer immunotherapy drugs called PD-1 inhibitors are widely used to stimulate the immune system to fight cancer, but many patients either don’t respond or develop resistance to them. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.

Now scientists have shown, in a study published in Nature, that the small molecule works through two different mechanisms to slow tumor growth and increase survival in lab animals.

Researchers from the Tumor Immunotherapy Discovery Engine (TIDE) at the Broad Institute of MIT and Harvard, AbbVie, and Calico Life Sciences report that the molecule simultaneously makes tumors more sensitive to immune attack and boosts the activity of immune cells to fight tumors in mice.

Within the last century different ways have been developed to fight cancer. The most recent type of therapy includes immunotherapy. Immunotherapy activates the immune system to recognize and target the tumor that was initially undetectable. The most common immunotherapy treatments include anti-programmed death-1 (anti-PD-1) and anti-cytotoxic T lymphocyte-associated antigen (anti-CTLA-4). The two therapies are known as checkpoint inhibitors because they block cell signaling between immune cells and cancer which allow immune cells to be activated and kill the tumor. For their work on both of these therapies, Dr. James Allison and Dr. Tasuku Honjo were awarded the Nobel Prize in Physiology or Medicine in 2018. Since the discovery of these checkpoint inhibitors, they have been used in multiple settings as single-agent therapies or in combination against many different cancers.

The use of checkpoint inhibitors before therapy or as a neoadjuvant has grown as a possible treatment in various cancer types. According to researchers at the Bloomberg-Kimel Institute for Cancer Immunotherapy and the Johns Hopkins Kimmel Cancer Center medicine, checkpoint inhibitors have just touched the surface in neoadjuvant immunotherapy. Researchers including Suzanne Topalian, Director of Johns Hopkins Melanoma/Skin Cancer Program, believe that cancer immunotherapy has a lot of rich untapped potential that can be used to further improve treatments.

Neoadjuvant immunotherapy, or therapy prior to surgery, has since been tested in various clinical trials. In some tumor types this form of therapy has resulted in complete tumor eradication. The report published in Cancer Cell highlights successful clinical trials in cancers such as lung, triple-negative breast, skin, and gastrointestinal. Although this therapy is still highly underdeveloped, the US Food and Drug Administration (FDA) has already approved neoadjuvant immunotherapy in triple-negative breast and lung cancer. It is expected that more approvals will follow for other cancer types.